Immune therapy eliminates tumor cells in early triple negative breast cancer

Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.

Leave a Reply

Your email address will not be published. Required fields are marked *